Aspirin resistance: moving forward with multiple definitions, different assays, and a clinical imperative.

Stewart M. Knoepp, Michael Laposata

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Many patients are treated with aspirin to prevent a serious vascular event, most notably myocardial infarction and stroke. A growing number of studies have been appearing in the literature that indicate a significant fraction of aspirin-treated patients may be resistant to the antiplatelet effects of the drug. Resistance to aspirin may be related to the concomitant ingestion of aspirin and nonsteroidal anti-inflammatory drugs, which impairs the aspirin effect, or to more complex situations, such as metabolic defects that diminish the therapeutic effect of aspirin. The incidence of aspirin resistance is unknown, but it may approach 20% to 30%. The diagnosis of aspirin resistance has been evaluated using multiple assays, and because there are multiple assays, this has resulted in multiple definitions for aspirin resistance. This review considers aspirin resistance at a time when there is confusion about the definition, and the clinical assay to best assess it, because there is a clinical imperative to know now which patients taking aspirin are not receiving a therapeutic effect.

Original languageEnglish (US)
JournalAmerican Journal of Clinical Pathology
Volume123 Suppl
StatePublished - Jun 2005
Externally publishedYes

Fingerprint

Aspirin
Therapeutic Uses
Platelet Aggregation Inhibitors
Blood Vessels
Anti-Inflammatory Agents
Eating
Stroke
Myocardial Infarction
Incidence

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

@article{8f83f441736c43a8ae8fea35d457a39b,
title = "Aspirin resistance: moving forward with multiple definitions, different assays, and a clinical imperative.",
abstract = "Many patients are treated with aspirin to prevent a serious vascular event, most notably myocardial infarction and stroke. A growing number of studies have been appearing in the literature that indicate a significant fraction of aspirin-treated patients may be resistant to the antiplatelet effects of the drug. Resistance to aspirin may be related to the concomitant ingestion of aspirin and nonsteroidal anti-inflammatory drugs, which impairs the aspirin effect, or to more complex situations, such as metabolic defects that diminish the therapeutic effect of aspirin. The incidence of aspirin resistance is unknown, but it may approach 20{\%} to 30{\%}. The diagnosis of aspirin resistance has been evaluated using multiple assays, and because there are multiple assays, this has resulted in multiple definitions for aspirin resistance. This review considers aspirin resistance at a time when there is confusion about the definition, and the clinical assay to best assess it, because there is a clinical imperative to know now which patients taking aspirin are not receiving a therapeutic effect.",
author = "Knoepp, {Stewart M.} and Michael Laposata",
year = "2005",
month = "6",
language = "English (US)",
volume = "123 Suppl",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",

}

TY - JOUR

T1 - Aspirin resistance

T2 - moving forward with multiple definitions, different assays, and a clinical imperative.

AU - Knoepp, Stewart M.

AU - Laposata, Michael

PY - 2005/6

Y1 - 2005/6

N2 - Many patients are treated with aspirin to prevent a serious vascular event, most notably myocardial infarction and stroke. A growing number of studies have been appearing in the literature that indicate a significant fraction of aspirin-treated patients may be resistant to the antiplatelet effects of the drug. Resistance to aspirin may be related to the concomitant ingestion of aspirin and nonsteroidal anti-inflammatory drugs, which impairs the aspirin effect, or to more complex situations, such as metabolic defects that diminish the therapeutic effect of aspirin. The incidence of aspirin resistance is unknown, but it may approach 20% to 30%. The diagnosis of aspirin resistance has been evaluated using multiple assays, and because there are multiple assays, this has resulted in multiple definitions for aspirin resistance. This review considers aspirin resistance at a time when there is confusion about the definition, and the clinical assay to best assess it, because there is a clinical imperative to know now which patients taking aspirin are not receiving a therapeutic effect.

AB - Many patients are treated with aspirin to prevent a serious vascular event, most notably myocardial infarction and stroke. A growing number of studies have been appearing in the literature that indicate a significant fraction of aspirin-treated patients may be resistant to the antiplatelet effects of the drug. Resistance to aspirin may be related to the concomitant ingestion of aspirin and nonsteroidal anti-inflammatory drugs, which impairs the aspirin effect, or to more complex situations, such as metabolic defects that diminish the therapeutic effect of aspirin. The incidence of aspirin resistance is unknown, but it may approach 20% to 30%. The diagnosis of aspirin resistance has been evaluated using multiple assays, and because there are multiple assays, this has resulted in multiple definitions for aspirin resistance. This review considers aspirin resistance at a time when there is confusion about the definition, and the clinical assay to best assess it, because there is a clinical imperative to know now which patients taking aspirin are not receiving a therapeutic effect.

UR - http://www.scopus.com/inward/record.url?scp=24044542986&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=24044542986&partnerID=8YFLogxK

M3 - Article

C2 - 16100874

AN - SCOPUS:24044542986

VL - 123 Suppl

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

ER -